Journals / Türkiye Çocuk Hastalıkları Dergisi / 2020 / Cilt: 14 - Sayı: EK SAYI 1

Cytokine Release Syndrome and Treatment in COVID-19

COVID-19’da Sitokin Salınım Sendromu ve Tedavi Yaklaşımları

Pages
55–59
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Here, theresponses of host cells, cytokine release syndrome and the therapeutic approaches to alleviate the cytokine storm inCOVID-19 will be reviewed.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The emergent outbreak of coronavirus disease 2019 (COVID-19) is a global health problem and has been recognizedas a pandemic.
📊
Key Findings & Data:Although COVID-19 leads to mild flu-like symptoms in most patients, the disease may cause frequentlyfatal, severe complications, such as acute respiratory distress syndrome and cytokine release syndrome.
💡
Conclusion & Impact:Here, theresponses of host cells, cytokine release syndrome and the therapeutic approaches to alleviate the cytokine storm inCOVID-19 will be reviewed.
🔬Design:Review & Systematic Survey
📍Scope:2019 Verileri
⚙️Variables:Domain Parameters

Abstract

The emergent outbreak of coronavirus disease 2019 (COVID-19) is a global health problem and has been recognizedas a pandemic. Although COVID-19 leads to mild flu-like symptoms in most patients, the disease may cause frequentlyfatal, severe complications, such as acute respiratory distress syndrome and cytokine release syndrome. In these patients, defects in lymphocytic cytolytic activity trigger the proinflammatory cytokine cascade, and then “cytokine storm”begins. As a result, it leads to uncontrolled active macrophage entry into the tissues and hemophagocytosis. Here, theresponses of host cells, cytokine release syndrome and the therapeutic approaches to alleviate the cytokine storm inCOVID-19 will be reviewed.

Özet

Yeni ortaya çıkan coronavirus hastalığı 2019 (COVID-19) küresel bir sağlık sorunudur ve pandemi olarak kabul edilmiştir. COVID-19, hastaların çoğunda hafif grip benzeri semptomlara yol açmasına rağmen, hastalık akut solunum sıkıntısı sendromu ve sitokin salınım sendromu gibi sıklıkla ölümcül, ciddi komplikasyonlara neden olabilir. Bu hastalarda lenfositik sitolitik aktivitedeki defektler proinflamatuar sitokin kaskadını tetiklemekte ve “sitokin fırtınasını” başlatmaktadır. Sonuç olarak, dokulara kontrolsüz aktif makrofaj girişine ve hemofagositoza yol açmaktadır. Burada, COVID-19’da konakçı hücrelerin yanıtları, sitokin salınım sendromu ve sitokin fırtınasını durdurmak için tedavi yaklaşımları ele alınmıştır.

🔖

Cite This Article

ACAR, B. C., KURT, T. (2022). Cytokine Release Syndrome and Treatment in COVID-19. Türkiye Çocuk Hastalıkları Dergisi, Cilt: 14 - Sayı: EK SAYI 1, 55–59. https://ajindex.com/articles/627090

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020;395:565–74
  2. Nazinitsky A, Rosenthal KS. Cytokine storms: systemic disasters of infectious diseases. Infect Dis Clin Pract 2010;18:188–92
  3. Behrens EM. Cytokines in cytokine storm syndrome. In: Cron RQ, Behrens EM. Cytokine Storm Syndrome. Cham: Springer International Publishing 2019;197–207
  4. Zhou Y, Fu B, Zheng X, Wang D, Zhao C, Qi Y, et al. Aberrant pathogenic GM-CSF+ T cells and inflammatory CD14+CD16+ monocytes in severe pulmonary syndrome patients of a new coronavirus. bioRxiv 2020; doi: 10.1101/2020.02.12.945576
  5. Maclean OA, Orton R, Singer J, Robertson DL. Response to “On the origin and continuing evolution of SARS-CoV-2”. 2020. http:// virological.org/t/response-to-on-the-origin-and-continuingevolution-of-sars-cov-2/418 (accessed March 7, 2020
  6. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 2020;8:420-2
  7. Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol 2017;39:529–39
  8. Liu T, Zhang J, Yang Y, Ma H, Li Z, Zhang J, et al. The potential role of IL-6 in monitoring severe case of coronavirus disease 2019. medRxiv 2020; doi: 10.1101/2020.03.01.20029769
  9. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395:507–13. 10
  10. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020; 323: 1061-9
  11. Yu L, Tong Y, Shen G, Fu A, Lai Y, Zhou X, et al. Immunodepletion with hypoxemia: a potential high risk subtype of coronavirus disease 2019. medRxiv 2020; doi: 10.1101/2020. 03.03.20030650
  12. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 2020;8:420-2
  13. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497–506
  14. Chen L, Liu HG., Liu W, Liu J, Liu K, Shang J. Analysis of clinical feat